Cargando…
A phase 3 trial evaluating panitumumab plus best supportive care vs best supportive care in chemorefractory wild-type KRAS or RAS metastatic colorectal cancer
BACKGROUND: We assessed the treatment effect of panitumumab plus best supportive care (BSC) vs BSC on overall survival (OS) in patients with chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer (mCRC) and report the first prospective extended RAS analysis in a phase 3 trial. METHODS: P...
Autores principales: | Kim, Tae Won, Elme, Anneli, Kusic, Zvonko, Park, Joon Oh, Udrea, Anghel Adrian, Kim, Sun Young, Ahn, Joong Bae, Valencia, Ricardo Villalobos, Krishnan, Srinivasan, Bilic, Ante, Manojlovic, Nebojsa, Dong, Jun, Guan, Xuesong, Lofton-Day, Catherine, Jung, A Scott, Vrdoljak, Eduard |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5104888/ https://www.ncbi.nlm.nih.gov/pubmed/27736842 http://dx.doi.org/10.1038/bjc.2016.309 |
Ejemplares similares
-
Best Supportive Care of the Patient with Oesophageal Cancer
por: Pichel, Rita Carrilho, et al.
Publicado: (2022) -
Cost-Effectiveness of Avelumab Maintenance Therapy Plus Best Supportive Care vs. Best Supportive Care Alone for Advanced or Metastatic Urothelial Carcinoma
por: Xie, Qian, et al.
Publicado: (2022) -
A Q-TWiST analysis comparing panitumumab plus best supportive care (BSC) with BSC alone in patients with wild-type KRAS metastatic colorectal cancer
por: Wang, J, et al.
Publicado: (2011) -
Decision-making factors for best supportive care alone and prognostic factors after best supportive care in non-small cell lung cancer patients
por: Kitazawa, Haruna, et al.
Publicado: (2019) -
Corrigendum: Cost-effectiveness of avelumab maintenance therapy plus best supportive care vs. best supportive care alone for advanced or metastatic urothelial carcinoma
por: Xie, Qian, et al.
Publicado: (2022)